相关实验视频
Updated: Jun 13, 2025

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
非流利的初级渐进性失言症及其与运动神经元疾病的关联
Sarah Geevarughese1, Rajul Parikh2
1Clinical, Biomedical, and Educational Research, Edward Via College of Osteopathic Medicine, Spartanburg, USA.
Cureus
|September 9, 2024
概括
前性痴呆症 (FTD) 和运动神经元疾病 (MND) 可以同时发生. 这一案例突出了罕见的非流利的初级渐进性失言症 (nvPPA) 与随后的MND症状,为诊断和预后提供了洞察力.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 痴呆症研究 痴呆症研究
背景情况:
- 前性痴呆症 (FTD) 是一种常见的痴呆症,其特征是前和叶退化 (FTLD).
- 初级渐进性失言症 (PPA) 是一种FTD变体,表现为语言障碍,其亚型包括语义 (svPPA),非流利 (navPPA) 和逻辑 (lvPPA).
- 运动神经元疾病 (MND) 涉及影响运动通路的渐进性神经元退化.
研究的目的:
- 报告一个罕见的非流利的初级渐进性失言症 (nvPPA) 病例,后来发展为运动神经元疾病 (MND) 症状.
- 讨论这种罕见的同时发生的诊断和预后影响.
- 为了解FTD-MND频谱做出贡献,特别是在PPA变体中.
主要方法:
- 案例研究介绍.
- 临床诊断和症状跟踪.
- 对FTD,PPA和MND协会的现有文献的审查.
主要成果:
- 一名69岁的女性最初被诊断为nvPPA,后来出现了与MND一致的临床症状.
- 这次演示是FTD-MND频谱中罕见的一例,涉及PPA变种.
- 这一案例强调了诊断和管理患有重叠神经退行性疾病的患者的复杂性.
结论:
- 虽然nvPPA和MND的同时发生很少见,但需要对这两种情况进行仔细的临床评估.
- 了解这种罕见的表现对于准确的诊断和有效的患者管理至关重要.
- 这一案例扩大了已知的FTD-MND协会的范围,特别是在电力购买合同子类型内.
相关概念视频
Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Chemical Synapses
8.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.8K
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Cross-bridge Cycle
117.1K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.1K
Myasthenia Gravis: Diagnostic Tests
699
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
699

